Advanced Cardiovascular Imaging of the Systemic Effects of Inflammasome Activation - Trial NCT05880355
Access comprehensive clinical trial information for NCT05880355 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Virginia and is currently Not yet recruiting. The study focuses on Myocardial Infarction. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Virginia
Timeline & Enrollment
Phase 1
Jan 01, 2024
Oct 30, 2028
Primary Outcome
Remote plaque volume
Summary
Subjects with urgently reperfused type I myocardial infarction (MI) will be recruited and
 randomized to receive either placebo or the oral inflammasome (NLRP3) inhibitor dapansutrile.
 The primarily outcome measure will be carotid plaque volume change over 6 months; secondary
 outcome measures will be plaque inflammatory activity and coronary microvascular function.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05880355
Non-Device Trial